Su1174 Sequential and Concomitant Treatments in H. pylori Eradication: A Network Meta-Analysis

confirmed with 13C-urea breath test 4-8 weeks after therapy. Compliance/tolerance: Compliance was determined through questioning and recovery of empty medication envelopes. Incidence of adverse effects was evaluated by means of a questionnaire. RESULTS: 700 consecutive patients were included (mean age 48 years, 46% males, 20% peptic ulcer and 80% functional of non-investigated dyspepsia): 344 in group A (standard) and 356 in group B (optimized). Compliance with treatment was 94.5% and 95.9% in groups A and B (nonstatistically significant differences). Per-protocol eradication rates in groups A and B were 87.7% (95%CI=84-91%) and 93.5% (91-96%) (p 90% (both by protocol and by intention-to-treat). This optimized regimen is more effective than the standard one. Although the incidence of adverse effects is higher with the optimized treatment, these are mostly mild, and do not negatively impact the compliance.